| http://www.w3.org/ns/prov#value | - Merck's program is the sixth drug candidate using our XmAb intellectual property currently in clinical trials and is the latest example of our technology offering partners an opportunity to create best-in-class therapeutics, said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.
|
